Cellebrite DI Ltd. $CLBT Shares Sold by William Blair Investment Management LLC

William Blair Investment Management LLC trimmed its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 12.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 482,817 shares of the company’s stock after selling 69,729 shares during the quarter. William Blair Investment Management LLC owned 0.20% of Cellebrite DI worth $8,947,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in CLBT. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Cellebrite DI by 16.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 173,013 shares of the company’s stock worth $3,362,000 after purchasing an additional 24,881 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in Cellebrite DI in the second quarter valued at $657,000. Teacher Retirement System of Texas boosted its position in shares of Cellebrite DI by 3.7% during the 2nd quarter. Teacher Retirement System of Texas now owns 46,065 shares of the company’s stock worth $737,000 after purchasing an additional 1,658 shares in the last quarter. Sigma Planning Corp increased its holdings in shares of Cellebrite DI by 100.0% in the 2nd quarter. Sigma Planning Corp now owns 24,000 shares of the company’s stock valued at $384,000 after purchasing an additional 12,000 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in shares of Cellebrite DI by 11.6% in the second quarter. Bank of New York Mellon Corp now owns 1,287,954 shares of the company’s stock valued at $20,607,000 after purchasing an additional 133,651 shares during the period. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI Stock Performance

CLBT stock opened at $13.74 on Wednesday. The stock’s 50 day moving average price is $15.84 and its 200 day moving average price is $16.98. The firm has a market cap of $3.29 billion, a P/E ratio of 44.32, a PEG ratio of 2.07 and a beta of 1.30. Cellebrite DI Ltd. has a 1 year low of $11.76 and a 1 year high of $20.86.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings data on Wednesday, February 11th. The company reported $0.14 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.14. The business had revenue of $128.82 million for the quarter, compared to the consensus estimate of $126.07 million. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.The business’s revenue was up 28.8% on a year-over-year basis. During the same period in the prior year, the business earned $0.10 earnings per share. On average, research analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on CLBT shares. JPMorgan Chase & Co. upped their target price on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. Bank of America upped their price target on Cellebrite DI from $24.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Lake Street Capital lifted their price objective on Cellebrite DI from $22.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cellebrite DI in a research report on Monday, December 29th. Finally, Needham & Company LLC dropped their price target on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, February 12th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $22.50.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.